77 results about "Instilling eye drops" patented technology

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention relates to an exosome composition, application thereof and exosome eye drops, and relates to the technical field of pharmaceutical preparations, and the exosome composition is composed of a mesenchymal stem cell exosome and a rabdosia lingua extract in a weight ratio of (5-10): (13-21). The exosome composition is composed of the mesenchymal stem cell exosome and the rabdosia lophanthoides extract in a proper proportion, and the mesenchymal stem cell exosome and the rabdosia lophanthoides extract are matched for use, so that the exosome composition has an excellent treatment effect on cataract and can be applied to preparation of products such as eye drops and the like, and a new treatment means is provided for cataract patients. In addition, the exosome eye drops provided by the invention do not contain side-effect components such as preservatives and hormones, have no obvious irritation and can be used for a long time.

The invention belongs to the technical field of biological medicines, and particularly relates to a dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle as well as a preparation method and application of the dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle. The STING inhibitor is wrapped in the lipidosome to obtain the lipidosome nano-drug, and the lipidosome is used as a drug carrier, so that the water solubility and bioavailability of the lipidosome nano-drug can be improved; meanwhile, the cell-penetrating peptide and the targeted cell-penetrating peptide are used for jointly modifying the liposome nano-drug, and the cell-penetrating peptide and the targeted cell-penetrating peptide synergistically improve the cell-penetrating performance, help the drug to penetrate through an eye barrier and target retinal vascular endothelial cells, and increase the bioavailability of the drug. Moreover, the obtained nanoparticles exist in a liquid form and can be directly used as eye drops for treating eyes with retinopathy, so that a convenient and non-invasive eye disease treatment mode can better benefit patients with retinopathy, reduce retinal angiogenesis of the patients and facilitate treatment and prognosis of diseases.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to emedastine fumarate eye drops and a preparation method thereof. The invention provides emedastine fumarate eye drops, the pH value of the emedastine fumarate eye drops is 7.2-7.6, and the emedastine fumarate eye drops are prepared from the following components in parts by weight: 0.84-0.92 part of emedastine fumarate, 2-3 parts of a thickening agent, 4.5-5.5 parts of a buffering agent, 6-8 parts of an osmotic pressure regulator, a pH regulator and 950-1050 parts of water, wherein the thickening agent is hydroxypropyl methylcellulose 2910. According to the emedastine fumarate eye drops disclosed by the invention, the hydroxypropyl methylcellulose 2910 is used as a thickening agent, so that the obtained emedastine fumarate eye drops are more clear, less in impurity content and higher in stability; meanwhile, a specific preparation method is limited, the dissolution time of the osmotic pressure regulator is greatly shortened, and the production efficiency is improved.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a cromolyn sodium eye drop without antioxidant. The cromolyn sodium eye drop comprises cromolyn sodium liposome and pharmaceutically acceptable additives; a formula is preferred in the preparation process of the cromolyn sodium liposome, so that the cromolyn sodium liposome has a high drug loading and encapsulation efficiency, and lays a foundation for further preparation into a preparation. In addition, the cromolyn sodium liposome eye drop of the application does not add antioxidant, and also has high stability, and is qualified in a sterile test and has high light stability.

The purpose of the present invention is to discover an eye drop capable of effectively lowering intraocular pressure even at night, especially during night sleep, in patients with glaucoma or ocular hypertension.　The present invention is an eye drop for lowering intraocular pressure during night sleep in patients suffering from glaucoma or ocular hypertension, the eye drop containing sepetaprost at a concentration of 0.002% (w / v) as an active ingredient.

The invention relates to a preparation method of brimonidine tartrate eye drops, particularly relates to a new technical scheme obtained by adjusting the rotating speed, the temperature and the material adding sequence, and solves the problems of non-uniform content of benzalkonium chloride and dissolution of polyvinyl alcohol. The brimonidine tartrate eye drops prepared by the preparation method disclosed by the invention are uniform in benzalkonium chloride content, clear in liquid medicine, stable in quality, low in requirements on production equipment and suitable for large-scale industrial production.

The invention relates to the technical field of medical analysis, in particular to a method for detecting the content of an antioxidant in bromfenac sodium eye drops through liquid chromatography, and particularly relates to a method for detecting the content of the antioxidant anhydrous sodium sulfite of the bromfenac sodium eye drops through high performance liquid chromatography. Wherein the mobile phase A is a methanol-buffer salt solution; a mobile phase B is methanol; eluting by using a gradient mobile phase, wherein the volume ratio of the mobile phase is 100%; preparing a reference solution and a test solution by taking the mobile phase A as a diluent, then respectively injecting the reference solution and the test solution into a liquid chromatograph, and recording chromatograms; calculating the content of anhydrous sodium sulfite by adopting an external standard method; the method comprises the following specific steps: (1) preparation of a reference substance solution: taking an anhydrous sodium sulfite reference substance, and adding a diluent for dissolving to obtain the reference substance solution; and (2) preparation of a test solution: taking the bromfenac sodium eye drops, and adding a diluent to dilute the bromfenac sodium eye drops to obtain the bromfenac sodium eye drops. The method disclosed by the invention is strong in specificity, high in stability, high in precision and high in accuracy, and has practical significance on quality control of the bromfenac sodium eye drops.

The utility model relates to the technical field of eye drop preparation, in particular to a pearl eyesight-improving eye drop preparation device which comprises a liquid preparation barrel, the upper end of the liquid preparation barrel is fixedly communicated with a liquid inlet pipe, the upper end of the liquid inlet pipe is fixedly connected with a liquid inlet cylinder, a round hole is formed in the side face of the liquid inlet cylinder, a liquid adjusting pipe is horizontally and fixedly installed in the round hole, and a liquid outlet pipe is fixedly installed in the liquid adjusting pipe. A mounting frame is fixedly mounted at one end of the adjusting liquid pipe, a threaded hole is formed in the mounting frame, an adjusting screw rod is inserted into the threaded hole in a threaded mode, a push block is fixedly mounted at one end of the adjusting screw rod, the push block is inserted into the adjusting liquid pipe in a sliding mode, and a plugging assembly is arranged in the round hole. When the amount of prepared liquid is too large, the round hole can be opened through the plugging assembly, then redundant prepared liquid is guided into the adjusting liquid pipe through mutual liquid preparation of the adjusting liquid pipe, the push block and the adjusting screw rod, the amount of the taken-out prepared liquid can be accurately controlled, repeated operation is not needed, operation is easy, and time and labor are saved.

The present invention relates to a fumarate metal-organic framework for treating ocular bacterial infections, and also relates to its use in treating ocular bacterial infections. The fumarate metal-organic framework is Zr / Fe@FA MOFs, the metal coordination ions are Zr(IV) and Fe(III), and the ligand is fumaric acid. The Zr / Fe@FA MOFs have excellent anti-biofilm activity, and their effect can be greatly improved when used in combination with levofloxacin. In addition, the present invention also provides an encapsulated microneedle system, Zr / Fe@FA MNs, which can deliver MOFs directly to bacterial microcolony lesion areas in 3D confined microenvironments through the precise penetration ability of microneedles, significantly enhancing the effectiveness of drugs in biofilm eradication. Zr / Fe@FA MNs can not only overcome the limitations of traditional eye drops in corneal permeability, but also achieve long-term treatment through the sustained release of MOFs and the slow-release properties of microneedles.

The invention relates to a method for determining the content of tobramycin in tobramycin eye drops, which comprises the following steps: 1) preparation of a reference substance solution: taking a tobramycin reference substance, and adding water and sulfuric acid to dissolve the tobramycin reference substance to prepare the reference substance solution; 2) preparation of a test solution: diluting tobramycin eye drops with water to prepare a reference solution; 3) preparation of derivatization solutions: respectively adding the reference substance solution and the test substance solution into a 2, 4-dinitrofluorophenethyl alcohol solution and a tris (hydroxymethyl) aminomethane solution for reaction, and adding acetonitrile after the reaction is completed to prepare a reference substance derivatization solution and a test substance derivatization solution; and 4) determination: taking the reference substance derivatization solution and the test sample derivatization solution, respectively injecting into a high performance liquid chromatograph to obtain chromatograms, and calculating the tobramycin content by using an external standard method according to the peak area of the chromatograms.

The invention relates to a drug sustained release system, in particular to lipid liquid crystal precursor eye drops as well as a preparation method and application thereof. The lipid liquid crystal precursor eye drops comprise a matrix material, a cosolvent and a raw material medicine, wherein the matrix material is an amphiphilic substance and an oil phase; the lipid liquid crystal precursor eye drops are prepared from the following components in percentage by weight: 0 to 35 percent of amphiphilic substance, 40 to 80 percent of oil phase, 15 to 20 percent of cosolvent and 0.001 to 5 percent of raw material medicine. According to the constructed drug-loaded lipid liquid crystal precursor eye drops, when the drug-loaded lipid liquid crystal precursor makes contact with water in tears, the drug-loaded lipid liquid crystal precursor can instantly become drug-loaded lipid liquid crystal gel, compared with common eye drops, the retention time of the drug-loaded lipid liquid crystal gel on the ocular surface is longer, the lipid liquid crystal has a phospholipid bilayer structure, and the drug-loaded lipid liquid crystal gel can be used for preparing the drug-loaded lipid liquid crystal precursor eye drops. Insoluble raw material medicines can be distributed in the lipid layer, so that the solubility of the raw material medicines is greatly improved, the raw material medicines can be slowly released by gelatinizing after meeting water, the administration frequency is reduced, the bioavailability and patient compliance are greatly improved, and the defects of the eye drops in treatment of glaucoma are overcome.

The invention designs a new application of grape seed procyanidine in prevention and treatment of cataract. The method comprises the following steps: constructing a cataract injury model by inducing rabbit crystalline lens oxidative injury with hydrogen peroxide, culturing by adopting a domestic rabbit crystalline lens, detecting the activity of total superoxide dismutase, glutathione peroxidase and catalase and the content of malondialdehyde by observing the opacity and structural form of the crystalline lens, and detecting the expression of apoptosis regulation proteins BCL-2 and BAX in combination with immunohistochemistry. And the protective effect and molecular mechanism of the grape seed procyanidine on crystalline lens injury are researched. Researches show that the grape seed procyanidine has a protective effect on hydrogen peroxide induced rabbit crystalline lens injury, and the mechanism of the grape seed procyanidine is related to an antioxidant effect and adjustment of BCL-2 / BAX apoptotic protein; rabbit eye stimulation experiments prove that the grape seed procyanidine has no stimulation or only slight stimulation to rabbit eyes. Therefore, the grape seed procyanidine can prevent cataract, is a potential cataract treatment medicine, provides a new way for development of related medical products such as eye drops, and has good clinical application value.

Cationic nanoparticles loaded with prostaglandins, and their preparation methods and applications. Prostaglandin-loaded lignin nanoparticles were prepared by nanoprecipitation method, and chitosan oligosaccharides or their derivatives were modified on the surface by electrostatic action. The particle size and surface charge of the nanoparticles were studied in detail by DLS, and the low cytotoxicity of the nanoparticles was confirmed by the CCK-8 method. The good in vivo safety was further verified by eye drops in animals for 14 days. It was also verified that cationic nanoparticles can prolong the ocular surface retention time of model drugs and reduce the expression of ZO-1. In the dexamethasone-induced high intraocular pressure model, the drug-loaded cationic nano eye drops achieved an intraocular pressure-lowering effect that was superior to naked drugs and anionic nano drugs. These nanoparticles are a new and efficient ocular drug delivery carrier with both long-term retention and ocular surface penetration.

The invention discloses a ruthenium-based nano-enzyme with eye infiltration capacity and a preparation method and application thereof, and relates to the technical field of medicine preparation, the ruthenium-based nano-enzyme is composed of a nano-enzyme matrix and fluorinated lipidosome wrapping the nano-enzyme matrix, and the nano-enzyme matrix is PolyRu with similar superoxide dismutase and catalase activity. According to the invention, the PolyRu nano-enzyme is encapsulated in the fluorinated liposome, so that the lipophilicity of the fluorinated liposome is enhanced, the fluorinated liposome can effectively penetrate through a cell membrane, the permeability of a medicine is further improved, and the non-invasive eye drops can be used for treating RND (Reduced Newcastle Disease); the technical problem that the existing nano-enzyme difficultly drips into eyeballs to effectively enter the eyeballs and is fully accumulated in the retina area to treat RND is solved.

The invention relates to the technical field of preparation of eye drops, in particular to diquafosol sodium eye drops and a preparation method thereof, and the diquafosol sodium eye drops comprise diquafosol sodium, disodium hydrogen phosphate, sodium chloride, potassium chloride, a preservative, a pH regulator and water for injection; wherein the preservative is a combination of boric acid, disodium ethylene diamine tetraacetate and polyvinylpyrrolidone. The diquafosol sodium eye drops can achieve the antibacterial efficacy meeting the standard, meanwhile, the damage of a preservative to the ocular surface of eyes can be effectively weakened, and the diquafosol sodium eye drops are prevented from causing secondary damage to the eye tissues of patients suffering from glaucoma, xerophthalmia and the like which need to be taken for a long time; the diquafosol sodium eye drop solves the problems that in the prior art, an existing diquafosol sodium eye drop is added with a preservative which greatly damages eyes, so that eye tissues are easily damaged or secondarily damaged, and potential risks are caused to the eyes due to the large addition amount of the preservative.

The invention provides oxygen-enriched eye drops based on oxygen-containing lipidosome and application of the oxygen-enriched eye drops. The preparation method comprises the following steps: firstly, preparing blank liposome powder through a film dispersion-freeze drying technology, carrying out oxygenation treatment on the blank liposome powder to prepare oxygen-containing liposome, and then mixing the oxygen-containing liposome with sodium hyaluronate eye drops to obtain the oxygen-enriched eye drops. According to the oxygen-enriched eye drops, the permeability of oxygen in corneal tissues is improved, proliferation of corneal epithelial cells is remarkably promoted, and the apoptosis process of the corneal epithelial cells is delayed. The oxygen-enriched eye drops can promote repair after corneal epithelium injury.

The application discloses a kind of zinc sulfide nanometer eye drops and its preparation method and application, the zinc sulfide nanometer eye drops includes zinc sulfide nanoparticles and sterile water, the zinc sulfide nanoparticles are spherical nanoparticles with pseudo-virus-like spike structure, and particle size is 150-250nm, and the zinc sulfide nanoparticles can release hydrogen sulfide gas under eye acidic inflammatory microenvironment.The application can realize the stable, slow, controllable release of hydrogen sulfide gas under eye acidic inflammatory microenvironment, utilize the anti-inflammatory, antioxidant, promote mucosa repair and improve tear film stability and other biological functions of gas signal molecule hydrogen sulfide, realize the effective treatment of dry eye, relieve eye dryness, inflammation, injury and other symptoms;The formula of the application is mild, has no obvious cytotoxicity and eye irritation, has good biological safety, can meet the needs of long-term, safe and comfortable use in clinic, provides a new, efficient and safe gas treatment approach for dry eye.

The application provides a kind of eye drop composition and its preparation method and application, belong to ophthalmic preparation technical field.The eye drop composition used in the application includes the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose, injection water;By compounding each component, a kind of eye drop capable of realizing brimonidine tartrate sustained release, prolonging the time of antihypertensive effect, and having the characteristics of reducing blinking discomfort, long-acting moisturizing, anti-inflammatory soothing, mild antiseptic, etc. is prepared;The eye drop of the application is helpful to glaucoma, high eye pressure, dry eye, postoperative inflammation or allergy, preservative-sensitive or preservative-allergic population, improves the quality of life, relieves the disease.

The invention belongs to the technical field of medicine. The invention relates to the field of eye drops, in particular to application of ipratropium bromide in the aspect of preventing or improving myopia and eye drops containing ipratropium bromide. The research proves that the single drug of the ipratropium bromide can effectively inhibit the growth of the ocular axis and the deterioration of the diopter, and the brand new medicinal value of the ipratropium bromide in the aspect of preventing and improving the myopia is disclosed for the first time. More importantly, the invention finds that the combination of the ipratropium bromide and the diquafosol sodium can generate a remarkable synergistic effect, and the curative effect of the combined preparation is far better than that of a single drug and even better than that of a clinical drug atropine. The invention provides a safe, effective and long-term brand new drug choice for myopia prevention and control, and has good application prospect and value.

The present invention provides a method for treating an ocular disorder in a subject in need thereof, comprising topically administering a therapeutically effective amount of a TRPM8 agonist to surfaces of ocular margin of the subject, wherein the ocular margin is the primary target site for delivery of the TRPM8 agonist. The method may use a wiping, brushing, or spraying approach, and is more effective and efficient than the conventional method using eye drops.

The online eye drop sterilization device comprises a sterilization barrel, a gas guide part, a liquid adding part and a liquid discharging part, the top end of the sterilization barrel is provided with an opening, the gas guide part is assembled at the opening end of the sterilization barrel, internal threads are formed in the top of the inner wall of the sterilization barrel, and the gas guide part comprises a screw cap; the screw cap is assembled at the opening end of the top end of the sterilization barrel in a threaded fit mode, the middle of the screw cap is vertically and rotatably connected with a flow dividing pipe in a penetrating mode, net cylinders are vertically and fixedly arranged at multiple ports of the bottom end of the flow dividing pipe in a penetrating mode, the top end of the flow dividing pipe is vertically and rotatably connected with an air guide pipe, and the top end of the air guide pipe communicates with a steam conveying pipeline; the liquid adding piece is arranged on one side of the screw cap in a communicating manner, and the problems that impurities and heat-resistant florae existing in base water cannot be killed in time when a heating ring of the cylinder body is used for sterilizing the base water in a heating manner, and the cleanliness of the base water sterilization is influenced by a single heating ring heating base water sterilization manner are solved.

The present application relates to a kind of dry eye drops, it includes by mass percentage: chondroitin sulfate 0.1%-0.5%, silk fibroin nanoparticles containing astaxanthin 0.06%-0.3%, sodium hyaluronate 0.1%-0.3%, vitamin E 0.05%-0.1%, sodium chloride 0.9-1.0%, poloxamer 0.05%-0.1%, EDTA 0.01%-0.1%, phosphate buffer and the balance of water;Wherein, the silk fibroin nanoparticles containing astaxanthin particle size is 50-300nm;Phosphate buffer is adjusted to 6.8-7.9 to the pH of eye drop.The eye drop of the present application can effectively relieve dry eye symptoms, provide long time wet and protection, while reducing eye inflammation and oxidative stress, significantly improve dry eye, and high use safety.

The invention discloses a levocetirizine hydrochloride eye drop composition as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The composition is prepared from levocetirizine hydrochloride, polyvinyl alcohol, povidone K30, sodium chloride, sodium benzoate, sodium hydroxide, hydrochloric acid and water, discomfort such as eye dryness caused by allergic conjunctivitis is remarkably relieved, and irritation caused by preservative sodium benzoate in multi-dose eye drops is reduced. The preparation method of the composition comprises the following steps: dissolving polyvinyl alcohol with a first part of water to obtain a product 1; dissolving povidone K30, sodium chloride and sodium benzoate with a second part of water, adjusting the pH value with sodium hydroxide and / or hydrochloric acid, and adding levocetirizine hydrochloride to obtain a product 2; and finally, adding the product 1 into the product 2, and supplementing water to the total amount. The composition is mainly used for treating eye itching related to allergic conjunctivitis. The levocetirizine hydrochloride eye drops provided by the invention do not contain antioxidants and buffering agents, and are non-irritant and good in stability.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention discloses brimonidine timolol eye drops and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The brimonidine and timolol eye drops disclosed by the invention contain 0.1-0.4% of brimonidine tartrate and 0.4-0.8% of timolol maleate in terms of mass volume concentration, and are matched with components of an osmotic pressure regulator, a buffer system, a stabilizer and the like in a specific proportion. According to the brimonidine timolol eye drops, drug degradation and impurity generation are remarkably reduced, the stability of the eye drops in a complex environment is greatly improved, and a higher-quality drug selection is provided for clinical treatment of open-angle glaucoma or intraocular hypertension.

The invention relates to a small molecule compound composition and application thereof, and belongs to the technical field of biology. The small molecule compound composition provided by the invention comprises NU7441, GW9662 and D609 or stereoisomers thereof. It is found for the first time that the small molecule compound combination can effectively inhibit oxidative damage caused by hypertonic to corneal epithelial cells, and the survival rate of the corneal epithelial cells is remarkably increased. Animal in-vivo experiments show that compared with a control group, an experimental group which is subjected to injection of scopolamine dry eye model mice and is subjected to eye drop of the small molecule compound combination eye drop at the same time has the advantages that corneal defects are obviously reduced, tear secretion is increased, the small molecule compound combination can effectively prevent corneal epithelium injury, the drug effect is relatively high, and no obvious drug toxicity exists; the small molecule compound combination may become a strong and effective medicine for clinically treating dry eye in the future.